Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

M&A Drives 3SBio’s Biosimilars Expansion Potential

This article was originally published in PharmAsia News

Executive Summary

3SBio has made its second acquisition for expanded product portfolio in biosimilars and antibodies since listing in Hong Kong. The majority stake buyout deal landed on the Chinese biosimilar and antibody developer Shanghai CP Guojian Pharmaceutical. Through the integration, two companies could develop oversea markets together.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC088615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel